DrugPatentWatch Database Preview
Drugs in Development Information for PF-06463922
Drug Development Status for PF-06463922: Patents, clinical trial progress, indications
PF-06463922 is an investigational drug.
There have been 12 clinical trials for PF-06463922.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 7th 2017.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Lymphoma, Large-Cell, Anaplastic. The leading clinical trial sponsors are Pfizer, Clinical Research Technology S.r.l., and National Cancer Institute (NCI).
There are nine US patents protecting this investigational drug and one hundred and thirty-two international patents.
Summary for PF-06463922
| US Patents | 9 |
| International Patents | 132 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 30 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2017-04-07) |
| Vendors | 41 |
Recent Clinical Trials for PF-06463922
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Lorlatinib in ALK Inhibitor‑Treated ALK‑Positive NSCLC in China | Pfizer | Phase 2 |
| Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol) | National Cancer Institute (NCI) | Phase 2 |
| A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma | Pfizer | Phase 2 |
Clinical Trial Summary for PF-06463922
Top disease conditions for PF-06463922
Top clinical trial sponsors for PF-06463922
US Patents for PF-06463922
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-06463922 | Start Trial | Substituted macrocycles useful as kinases inhibitors and methods of use thereof | Teligene Ltd. (Suzhou, CN) | Start Trial |
| PF-06463922 | Start Trial | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| PF-06463922 | Start Trial | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| PF-06463922 | Start Trial | Macrocyclic derivatives for the treatment of diseases | Pfizer Inc. (New York, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-06463922
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-06463922 | China | 107207528 | 2034-08-20 | Start Trial |
| PF-06463922 | European Patent Office | 3183256 | 2034-08-20 | Start Trial |
| PF-06463922 | Japan | 2017525716 | 2034-08-20 | Start Trial |
| PF-06463922 | Argentina | 102035 | 2034-07-21 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
